Interim CEO
Mikaela Bruhammar (b. 1976) has 20 years of experience working at major global life-science companies. She has held several strategic commercial roles and senior management positions in the Nordic region, on global and HQ level. During 1999-2008, various commercial roles with MSD Sweden AB, 2008-2012 local marketing and strategic roles with AstraZeneca Sweden and Nordic-Baltic. From 2012 to 2015 she was the Global Head of Astra Zeneca’s Vaccine Franchise, from 2015-2019 Vice President of Nordic-Baltic Business Unit in Respiratory, Inflammation and Autoimmune disease (RIA). In Aug 2019 she joined Real World Solutions at IQVIA, heading up the EMEA Practice for Real World Data and Evidence solutions. From 2021 – August 2023 she served as a board member at BC Platforms. In addition she also serves as a board member at Ziccum AB.
Ms. Bruhammar holds a MSc Molecular Biology degree, Linköping University, Sweden.